🇺🇸 FDA
Patent

US 7332471

Cross-linked glycopeptide-cephalosporin antibiotics

granted A61KA61K38/00A61P

Quick answer

US patent 7332471 (Cross-linked glycopeptide-cephalosporin antibiotics) held by Theravance, Inc. expires Mon Feb 14 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Feb 19 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 14 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K38/00, A61P, A61P31/04